skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Bictegravir  Audio icon

Other Names: BIC, GS-9883, bictegravir sodium
Drug Class: Integrase Inhibitors
Molecular Formula: C21 H18 F3 N3 O5
Registry Number: 1611493-60-7 (CAS)
Chemical Name: 2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, (2R,5S,13aR)-
Company: Gilead Sciences, Inc.
Phase of Development: Phase III, as part of a fixed-dose combination (FDC) product containing bictegravir/emtricitabine/tenofovir alafenamide.
Print

Chemical Image:
Click image to enlarge
Bictegravir
Bictegravir
Molecular Weight: 449.3832
(Compound details obtained from ChemIDplus Advanced,1 NIAID Therapeutics Database,2 and Gilead Sciences website3)

What is an investigational drug?

An investigational drug is one that is under study and is not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.

To learn more about investigational drugs, read the AIDSinfo What is an Investigational HIV Drug? fact sheet.

What is bictegravir?

Bictegravir (also known as GS-9883) is an investigational drug that is being studied for the treatment of HIV infection.4,5

Bictegravir belongs to a class (group) of HIV drugs called integrase inhibitors.4,5 Integrase inhibitors block an HIV enzyme called integrase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body.

Bictegravir can be taken once a day and does not require boosting with an additional drug.4,5 (Boosting involves the use of a second drug to increase the effectiveness of the main [first] drug.)

In vitro studies have shown that bictegravir may be effective against strains of HIV that are no longer affected by other HIV medicines.4,6,7 (In vitro refers to studies done in test tubes or other laboratory equipment and not on animals or humans.)

Bictegravir is currently being studied as a component of a fixed-dose combination (FDC) drug for the treatment of HIV infection. (Fixed-dose combination drugs include two or more drugs in a single dosage form, such as a capsule or tablet.) Bictegravir is being studied in a single-tablet combination of bictegravir/emtricitabine/tenofovir alafenamide.6,7

How are clinical trials of investigational drugs conducted?

Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.8

  • Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
  • Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
  • Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.8

In most cases, an investigational drug must be proven effective and must show continued safety in a Phase III clinical trial to be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.8

In what phase of testing is bictegravir?

Bictegravir, as part of an FDC tablet, is currently being studied in Phase III clinical trials.3

What are some studies on bictegravir?

Study Name: GS-US-141-1219; NCT02275065
Sponsor: Gilead Sciences
Phase: Ib
Location: United States
Participants:

  • The study involved HIV-infected adults who had either previously taken HIV medicines (called treatment-experienced) or who had never taken HIV medicines before entering the study (called treatment-naive).
  • Treatment-experienced particpants had never taken integrase inhibitors and had stopped antiretroviral therapy (ART) for at least 12 weeks before entering the study.
  • All participants had viral load levels (the amount of HIV in a blood sample) between 10,000 copies/mL and 400,000 copies/mL at the start of the study. They also had CD4 counts greater than 200 cells/mm3. (A CD4 count is a laboratory test that measures the number of CD4 cells in a sample of blood and is an important indicator of immune function. The CD4 count of a healthy person ranges from 500 to 1,600 cells/mm3.)

Purpose: The purpose of this study was to evaluate the safety, effectiveness, and drug properties of different doses of bictegravir.9

For more details on this study, see the Health Professional version.

Study Name: GS-US-141-1475; NCT02397694
Sponsor: Gilead Sciences
Phase: II
Location: United States
Participants: This study involves HIV-infected, treatment-naive adults with viral loads of at least 1,000 copies/mL and CD4 counts of at least 200 cells/mm3 at the start of the study.
Purpose: The purpose of this study is to compare the safety and effectiveness of bictegravir to the FDA-approved integrase inhibitor dolutegravir (brand name: Tivicay). All participants will receive the FDA-approved FDC drug emtricitabine/tenofovir alafenamide (brand name: Descovy) along with either bictegravir or dolutegravir.10

For more details on this study, see the Health Professional version.

Study Name: GS-US-380-1490; NCT02607956
Sponsor: Gilead Sciences
Phase: III
Location: North America, Australia, Europe, Africa
Participants: The study involves HIV-infected, treatment-naive adults with viral loads of at least 500 copies/mL at the start of the study.
Purpose: The purpose of this study is to evaluate the safety and effectiveness of the bictegravir/emtricitabine/tenofovir alafenamide FDC tablet versus dolutegravir plus Descovy.11

For more details on this study, see the Health Professional version.

Study Name: GS-US-380-1489; NCT02607930
Sponsor: Gilead Sciences
Phase: III
Location: North America and Europe
Participants: The study involves HIV-infected, treatment-naive adults with viral loads of at least 500 copies/mL at the start of the study.
Purpose: The purpose of this study is to evaluate the safety and effectiveness of the bictegravir/emtricitabine/tenofovir alafenamide FDC tablet versus the FDA-approved FDC drug abacavir/dolutegravir/lamivudine (brand name: Triumeq).12

For more details on this study, see the Health Professional version.

Three additional Phase III studies (NCT02603120, NCT02652624, and NCT02603107) will evaluate the use of the bictegravir/emtricitabine/tenofovir alafenamide FDC tablet in participants whose viral loads are suppressed by a stable ART regimen. These studies will determine the safety and effectiveness of switching participants to the bictegravir/emtricitabine/tenofovir alafenamide FDC tablet versus continuing their original ART regimen. Two of these studies (NCT02603120 and NCT02652624) are currently recruiting participants.13-15

What side effects might bictegravir cause?

In the Phase Ib study (NCT02275065) discussed under the previous question, bictegraivr was reported as being “well-tolerated” by participants at all doses. No serious side effects occurred and no participants stopped taking bictegravir during the study because of a side effect.16,17

Because bictegravir is still being studied, information on possible side effects of the drug is not complete. As testing of bictegravir continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying bictegravir?

More information about bictegravir-related research studies is available from the AIDSinfo database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.

I am interested in participating in a clinical trial of bictegravir. How can I find more information about participating in a clinical trial?

Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.8

Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.

References

  1. United States National Library of Medicine. ChemIDplus Advanced. Available at: http://chem.sis.nlm.nih.gov/chemidplus/rn/1611493-60-7. Last accessed on July 26, 2016.
  2. National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Available at: http://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx. Last accessed on July 26, 2016
  3. Gilead Sciences website. Pipeline. Available at: http://www.gilead.com/research/pipeline. Last accessed on July 26. 2016.
  4. White K, Cihlar T, Miller MD. Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance. American Society for Microbiology (ASM) Microbe; June 16-20, 2016; Boston, MA. Levin: National AIDS Treatment Advocacy Project (NATAP); HIV Articles; 2016. Available at: http://www.natap.org/2016/HIV/062316_02.htm. Last accessed on July 26, 2016.
  5. Tsiang M, Kan E, Tsai L, et al. Antiviral Activity of GS-9883, a Potent Next Generation HIV-1 Integrase Strand Transfer Inhibitor. American Society for Microbiology (ASM) Microbe; June 16-20, 2016; Boston, MA. Levin: Antiviral Activity of Bictegravir (GS-9883), a Potent Next Generation HIV-1 Integrase Strand Transfer Inhibitor; National AIDS Treatment Advocacy Project (NATAP); HIV Articles; 2016. Available at: http://www.natap.org/2016/HIV/062016_04.htm. Last accessed on July 26, 2016.
  6. Jones G, Goldsmith J, Mulato A, et al. GS-9883, a Novel HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Optimized In Vitro Resistance Profile. American Society for Microbiology (ASM) Microbe; June 16-20, 2016; Boston, MA. Levin: Bictegravir (GS-9883), a Novel HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Optimized In Vitro Resistance Profile; National AIDS Treatment Advocacy Project (NATAP); HIV Articles; 2016. Available at: http://www.natap.org/2016/HIV/062016_03.htm. Last accessed on July 26, 2016.
  7. Lazerwith SE, Cai R, Chen X, et al. Discovery of Gs-9883, an HIV-1 Integrase Strand Transfer Inhibitor (Insti) with Improved Pharmacokinetics and In Vitro Resistance Profile. American Society for Microbiology (ASM) Microbe; June 16-20, 2016; Boston, MA. Levin: Discovery of Bictegravir (GS-9883), a Novel, Unboosted, Once-Daily HIV-1 Integrase Strand Transfer Inhibitor (INSTI) with Improved Pharmacokinetics and In Vitro Resistance Profile; National AIDS Treatment Advocacy Project (NATAP); HIV Articles; 2016. Available at: http://www.natap.org/2016/HIV/062016_05.htm. Last accessed on July 26, 2016.
  8. National Institutes of Health (NIH). NIH Clinical Research Trials and You. Available at: https://www.nih.gov/health-information/nih-clinical-research-trials-you. Last accessed on July 26, 2016.
  9. Gilead Sciences. A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 23, 2014. NLM Identifier: NCT02275065. Available at: https://clinicaltrials.gov/ct2/show/NCT02275065. Last accessed on July 26, 2016.
  10. Gilead Sciences. A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 20, 2015. NLM Identifier: NCT02397694. Available at: https://clinicaltrials.gov/ct2/show/NCT02397694. Last accessed on July 26, 2016.
  11. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02607956. Available at: https://clinicaltrials.gov/ct2/show/NCT02607956. Last accessed on July 26, 2016.
  12. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02607930. Available at: https://clinicaltrials.gov/ct2/show/NCT02607930. Last accessed on July 26, 2016.
  13. Gilead Sciences. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02603120. Available at: https://clinicaltrials.gov/ct2/show/NCT02603120. Last accessed on July 26, 2016.
  14. Gilead Sciences. A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 8, 2016. NLM Identifier: NCT02652624. Available at: https://clinicaltrials.gov/ct2/show/NCT02652624. Last accessed on July 26, 2016.
  15. Gilead Sciences. A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 10, 2015. NLM Identifier: NCT02603107. Available at: https://clinicaltrials.gov/ct2/show/NCT02603107. Last accessed on July 26, 2016.
  16. Gallant J, Thompson M, DeJesus E, et al. Novel Insti Gs-9883 10 Day Monotherapy in Hiv-1-Infected Subjects. American Society for Microbiology (ASM) Microbe; June 16-20, 2016; Boston, MA. Levin: Novel Integrase Strand Transfer Inhibitor Bictegravir 10 Day Monotherapy in HIV-1-Infected Patients; National AIDS Treatment Advocacy Project (NATAP); HIV Articles; 2016. Available at: http://natap.org/2016/HIV/062016_01.htm. Last accessed on July 26, 2016.
  17. Gallant J, Thompson M, Mills T, et al. Novel Insti Gs-9883 10 Day Monotherapy in Hiv-1 Infected Subjects. Abstract presented at: American Society for Microbiology (ASM) Microbe; June 16-20, 2016; Boston, MA. Abstract 415. Available at: http://www.asmmicrobe.org/images/AbstractsUpdated.pdf. Last accessed on July 26, 2016.

 


Last Reviewed: July 28, 2016

Back to Top